Zoetis Inc. (NYSE:ZTS) Shares Purchased by Financial Advocates Investment Management

Financial Advocates Investment Management boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 81.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,273 shares of the company’s stock after buying an additional 2,822 shares during the period. Financial Advocates Investment Management’s holdings in Zoetis were worth $1,022,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. State Street Corp grew its position in Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after acquiring an additional 95,856 shares during the period. Geode Capital Management LLC lifted its stake in shares of Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after purchasing an additional 185,364 shares during the last quarter. Mizuho Securities USA LLC grew its holdings in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after purchasing an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Zoetis by 5.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after buying an additional 194,542 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after buying an additional 279,092 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 1.6 %

ZTS stock opened at $171.37 on Friday. The company’s 50 day moving average price is $169.34 and its 200 day moving average price is $179.28. The firm has a market capitalization of $77.32 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis’s payout ratio is 37.59%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ZTS. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Morgan Stanley cut their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Finally, Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Buy” and an average target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.